Kolexia
Robert Lucie Oncologie médicale
Robert Lucie
Oncologie médicale
Centre Eugène Marquis
Rennes, France
46 Activités
75 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du sein triple-négatives Carcinome pulmonaire non à petites cellules Tumeurs du poumon Carcinome épidermoïde Carcinomes Neurofibromatose de type 1 Tumeurs de la tête et du cou Carcinome épidermoïde de la tête et du cou

Collaborateurs

Voir plus
Crouzet Laurence
Crouzet Laurence
Centre Eugène Marquis, Rennes, France
Deleuze Antoine
Deleuze Antoine
Centre Eugène Marquis, Rennes, France
Le Du Fanny
Le Du Fanny
Centre Eugène Marquis, Rennes, France
De La Motte Rouge Thibault
De La Motte Rouge Thibault
Centre Eugène Marquis, Rennes, France

Industries

Voir plus
GSK
4 collaboration(s)
Dernière en 2023
VIATRIS MEDICAL
1 collaboration(s)
Dernière en 2022
Daiichi Sankyo
1 collaboration(s)
Dernière en 2023
Novartis
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.
Molecular oncology   29 janvier 2024
CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.
Cancer research   18 septembre 2023
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Oncogene   06 juin 2023
Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.
Clinica chimica acta; international journal of clinical chemistry   25 avril 2023
Abstract 3239: Selective depletion of regulatory T cells by ALD2510, a novel IL-2-sparing anti-CD25 antibody, synergizes with PD-1 blockade in breast and gynecologic cancers
Proceedings: AACR Annual Meeting 2023   01 avril 2023
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Oncogene   07 janvier 2023
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.
ESMO open   21 décembre 2022
Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer.
Cancer research   03 novembre 2022
144P Development of a 6-color multiplex crystal digital PCR assay for the simultaneous detection of ESR1 and PIK3CA mutations in the plasma of metastatic breast cancer patients
Molecular Analysis for Precision Oncology Congress 2022 14-16 October 2022   01 octobre 2022
Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Scientific reports   27 août 2021